---
title: "Tasly Pharmaceutical’s Nine-Month Financials Show Increased Profit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262587894.md"
description: "Tasly Pharmaceutical reported its unaudited financial results for the nine months ending September 30, 2025, showing a slight decrease in revenue but a notable increase in net profit compared to the previous year. The financials indicate positive cash flow and a stable asset base, reflecting a solid financial position. This could influence China Resources Pharmaceutical Group’s market standing and investor confidence, as the group holds a 28% equity interest in Tasly. Current market cap for China Resources is HK$30.6B with a technical sentiment signal to sell."
datetime: "2025-10-24T09:42:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262587894.md)
  - [en](https://longbridge.com/en/news/262587894.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262587894.md)
---

# Tasly Pharmaceutical’s Nine-Month Financials Show Increased Profit

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an announcement.

Tasly Pharmaceutical reported its unaudited financial results for the nine months ending September 30, 2025, showing a slight decrease in revenue but a notable increase in net profit compared to the previous year. The financials reveal a positive cash flow change and a stable asset base, suggesting a solid financial position for Tasly, which could impact China Resources Pharmaceutical Group’s overall market standing and investor confidence.

**More about China Resources Pharmaceutical Group Ltd.**

China Resources Pharmaceutical Group Ltd. is a prominent player in the pharmaceutical industry, focusing on manufacturing and distributing a wide range of pharmaceutical products. The company holds a significant market position, with a 28% equity interest in Tasly Pharmaceutical, a subsidiary listed on the Shanghai Stock Exchange.

**Average Trading Volume:** 16,744,630

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$30.6B

Learn more about 3320 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [600535.CN](https://longbridge.com/en/quote/600535.CN.md)

## Related News & Research

- [PXT: Production guidance nearly doubles for H2 2026, driven by acquisitions and exploration success](https://longbridge.com/en/news/296393798.md)
- [Nasdaq Futures Plunge as Rising Bond Yields Drive Chip Selloff](https://longbridge.com/en/news/296216952.md)
- [Demant hearing care chief Niels Wagner sells shares worth DKK 1.47 million](https://longbridge.com/en/news/296345010.md)
- [REG - Maven Inc&Grwth 5 - Unaudited NAV - Dividend Investment Scheme](https://longbridge.com/en/news/296374039.md)
- [REG - Maven IncGwth VCT 3 - Unaudited NAV - Dividend Investment Scheme](https://longbridge.com/en/news/296374036.md)